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Summary
Background: Delayed gadolinium enhancement (DGE) in cardiac magnetic resonance
(CMR) imaging indicates the areas with myocardial ﬁbrosis, which are suggested
to be arrhythmogenic substrate in hypertrophic cardiomyopathy (HCM). Elevated
brain natriuretic peptide (BNP) is associated with cardiovascular events in HCM. We
investigated the grade of DGE in CMR and plasma BNP levels in HCM patients with or
without symptomatic ventricular tachycardia (VT) or ventricular ﬁbrillation (VF).
Methods and results: We recruited 26 consecutive untreated HCM patients without
any symptoms of heart failure. They were divided into 2 groups: (1) patients withVentricular tachycardia
symptomatic VT/VF [VT/VF(+) group, n = 6]; (2) patients without symptomatic VT/VF
[VT/VF(−) group, n = 20]. CMR was performed to evaluate left ventricular geometry
and the grade of DGE. Plasma BNP levels, left ventricular mass index, and the num-
ber of segments with positive DGE were greater in the VT/VF(+) group than in the
VT/VF(−) group (698.1± 387.6 vs. 226.9± 256.8 pg/ml, p = 0.006; 152.3± 49.5 vs.
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89.5± 24.1 g/m2, p = 0.003; 9.7± 5.7 vs. 3.5± 3.3, p = 0.013). On logistic regression,
adjusted odds ratio for symptomatic VT/VF was 214 for log BNP (95% conﬁdence
interval [CI] 1.2—37,043, p = 0.04) and 1.54 for DGE score (95% CI 1.01—2.34, p = 0.04).
Conclusions: High plasma BNP levels and the enlarged area of DGE in CMR were asso-
ciated with symptomatic ventricular tachyarrhythmia. These factors may be useful
markers for detecting high-risk patients of sudden cardiac death in HCM.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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ntroduction
he great threat from hypertrophic cardiomyopa-
hy (HCM) is sudden cardiac death especially in
hildren and young adults. The incidence is cer-
ainly low at 2—3% per year in adults and 4—6%
n children, but risk stratiﬁcation of sudden death
s a major diagnostic challenge [1]. It is gener-
lly believed, although not established, that sudden
ardiac death is due to ventricular arrhythmia [2].
he risk of sudden cardiac death increases with clin-
cal risk factors such as non-sustained ventricular
achycardia (VT), syncope, exercise blood pressure
esponse, family history of sudden death, extreme
eft ventricular hypertrophy (LVH), marked left ven-
ricular (LV) outﬂow tract obstruction, and coronary
icrovascular dysfunction [1,3,4]. These markers
ave high negative predictive accuracy, but low
ositive predictive accuracy [1]. Thus, more sen-
itive markers of high-risk patients are needed.
Delayed gadolinium enhancement (DGE) in
ardiac magnetic resonance (CMR) imaging is
ndicative of the areas with replacement scar-
ing, which could be an arrhythmogenic substrate,
n patients with HCM [5]. DGE in CMR has been
eported to be associated with markers of sudden
eath [6] and VT detected by Holter monitoring
7,8] in HCM. However, there are no data that indi-
ate the association of DGE in CMR and symptomatic
ustained VT/ventricular ﬁbrillation (VF).
Plasma brain natriuretic peptide (BNP) level is
ncreased in patients with HCM [9]. Plasma BNP/N-
erminal (NT) pro-BNP concentration has been
hown to correlate with risk factors of sudden death
uch as LV wall thickness [10—14], LV outﬂow tract
bstruction [13,15], or silent myocardial ischemia
16] in patients with HCM. Plasma NT pro-BNP levels
ere associated with clinical deterioration, deﬁned
s a composite of cardiovascular death and hos-
italization for worsening heart failure symptoms
n HCM patients with New York Heart Association
NYHA) functional class I—III [17]. However, it is
nknown whether plasma BNP levels are useful in
dentifying high-risk patients in HCM without heart
ailure. Moreover, the relationship between plasma
E
I
d
cNP levels and DGE in CMR has not been reported
o date.
In this study, we analyzed HCM patients with-
ut symptoms of heart failure in order to deﬁne
hether DGE in CMR or plasma BNP levels are
ssociated with symptomatic ventricular tach-
arrhythmia.
ethods
atients characteristics
e studied 26 consecutive patients who were
ewly diagnosed as HCM. They were free from
ny symptom of heart failure (NYHA class I)
18 men, 8 women; mean age 67± 12 years)
nd took no medications. The diagnosis of
CM was based on the typical clinical, electro-
ardiographic, and hemodynamic features, with
chocardiographic demonstration of nondilated,
symmetrically hypertrophied left ventricle in the
bsence of other cardiac or systemic disease
hat may produce LV hypertrophy [18,19]. Twenty
atients were referred to the Hospital of Hyogo Col-
ege of Medicine because of incidentally found ECG
bnormality [VT/VF(−) group]. No patients had his-
ories of syncope or cardiac arrest in this group. Six
atients were referred to our hospital because of
ymptomatic sustained VT or VF [VT/VF(+) group].
mong these patients, three were survivors of
F. The other 3 patients had histories of syn-
ope and were proven to have sustained VT by
olter monitoring or electrophysiological studies.
xclusion criteria were organic coronary stenosis,
alvular heart disease, or systemic hypertension
≥140/90mmHg). Plasma BNP concentration was
easured using noncompetitive immunoradiomet-chocardiography
n all patients, conventional M-mode and 2-
imensional echocardiographic study with Doppler
olor ﬂow imaging was performed by experienced
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Figure 1 The schematic represents the segmentation as recommended by the American Heart Association and the
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BNP levels. LVMI was not included because it wasAmerican College of Cardiology [21]. Sixteen segments w
and 1 segment was evaluated in long-axis view (1-apex).
sonographers. Asymmetric septal hypertrophy was
deﬁned as the thickness of septum/free wall ≥1.3.
The presence of the intraventricular pressure gra-
dient was evaluated with continuous-wave Doppler
using a simpliﬁed Bernoulli equation (P = 4v2,
where P is pressure and v is ﬂow velocity). Obstruc-
tive HCM (HOCM) was deﬁned as a presence of an
intraventricular pressure gradient of greater than
30mmHg [20].
CMR technique and image analysis
CMR (Philips Intera 1.5T, Best, Netherlands) was
performed using steady-state, free precession
breath-hold cines in the long-axis planes and
sequential 8-mm short-axis slices from the atri-
oventricular ring to the apex. The DGE images were
acquired 15min after intravenous diethylene tri-
amine pentaacetic acid (DTPA, 0.1mmol/kg)
in the identical short-axis planes using an
inversion-recovery gradient echo sequence.
Inversion times were adjusted to null normal
myocardium.
LV mass and visual signal analysis was per-
formed on an off-line work station (Virtual Place,
Aze, Tokyo, Japan). LV function was analyzed from
the serial short-axis cine loops using manual seg-
mentation. End-systolic volume (ESV), end-diastolic
volume (EDV), LV ejection fraction (LVEF), inter-
ventricular septal wall thickness (IVST), and LV
mass index (LVMI) were calculated. For the DGE
image, hyperenhancement was considered to be
h
s
t
t
sevaluated in short-axis view (6-basal, 6-mid, 4-apical),
resent only if it was also present in the same slice
fter swapping phase encoding; thus artifact was
xcluded. The grade of DGE was evaluated using the
tandard LV 17-segment model [21] (Fig. 1). Pres-
nce or absence of DGE was visually judged by the
onsensus of two observers, and the number of LV-
egments with hyperenhancement was deﬁned as
GE score.
tatistical analysis
alues are expressed as means± S.D. All statisti-
al analyses were performed using a commercially
vailable statistical software (STATVIEW version
.0, SAS Institute Inc., Cary, NC, USA). Com-
arison of variables between the 2 groups was
erformed by using Mann—Whitney U-test. Eval-
ation of differences between proportions was
erformed by Chi-square test. Linear regression
nalysis was performed to correlate DGE in CMR,
VMI, and plasma BNP levels. Non-adjusted and
djusted odds ratio that explains symptomatic sus-
ained VT/VF was assessed with univariate and
ultivariate logistic analysis. Multivariate logistic
egression model included DGE in CMR and plasmaighly correlated with DGE in CMR. BNP data were
ubjected to logarithmic transformation (log) in
hese analyses because they were not normally dis-
ributed. We took p-value < 0.05 to be statistically
igniﬁcant.
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Table 1 Patient characteristics
VT/VF(+) VT/VF(−) p-Value
N 6 20 NS
Age (years) 55± 16 71± 8 p = 0.023
Male gender (n) 4 14 NS
HOCM (n) 1 5 NS
APH (n) 2 7 NS
ASH (n) 3 5 NS
BNP (pg/ml) 698.1± 387.6 226.9± 256.8 p = 0.0062
Echocardiographic data
LAD (mm) 43± 8 41± 7 NS
LVDd (mm) 46± 3 46± 5 NS
LVDs (mm) 27± 5 28± 5 NS
IVST (mm) 18± 7 13± 4 NS
EF (%) 67± 6 68± 8 NS
E velocity (m/s) 54± 18 69± 21 NS
E/A ratio 0.97± 0.40 0.97± 0.46 NS
E′ 4± 1 5± 2 NS
E/E′ ratio 16.1± 9.6 14.4± 5.4 NS
E deceleration time (ms) 293± 70 239± 82 NS
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sVT, ventricular tachycardia; VF, ventricular ﬁbrillation; HOCM, h
cardiomyopathy; ASH, asymmetric septal hypertrophy; LAD, le
LVDs, left ventricular end systolic diameter; IVST, interventric
esults
atients were younger in the VT/VF(+) group than in
he VT/VF(−) group (Table 1). There were no differ-
nces in gender and cardiac morphology assessed
ith conventional echocardiography between the
groups. Plasma BNP was higher in the VT/VF(+)
roup than in the VT/VF(−) group.
Fig. 2 shows a representative case in the
T/VF(−) group with low plasma BNP concentration
nd low DGE score. Fig. 3 shows a representative
ase in the VT/VF(+) group with high plasma BNP
oncentration and high DGE score.
There were no signiﬁcant differences in CMR
arameters of cardiac geometry such as EDV, ESV,
VEF, and IVST between the VT/VF(+) group and
he VT/VF(−) group (Fig. 4A—D). However, LVMI
nd the number of segments with positive DGE
ere greater in the VT/VF(+) group than in the
T/VF(−) group (152.3± 49.5 vs. 89.5± 24.1 g/m2,
= 0.003; 9.7± 5.7 vs. 3.5± 3.3, p = 0.01) (Fig. 4E
nd F). DGE score was correlated with LVMI
r = 0.48, p = 0.01). The correlation between plasma
NP level and LVMI or DGE score did not reach
tatistical signiﬁcance(r = 0.363, p = 0.07; r = 0.37,
= 0.06, respectively). In the study population,
on-adjusted odds ratio for symptomatic VT/VF
as 64.2 for log BNP (95% conﬁdence interval [CI]
.7—2419.6, p = 0.02), 1.42 for DGE score (95%
I 1.04—1.96, p = 0.03) and 1.07 for LVMI (95%
I 1.01—1.12, p = 0.02). Adjusted odds ratio for
m
i
[
i
itrophic obstructive cardiomyopathy; APH, apical hypertrophic
rial dimension; LVDd, left ventricular end-diastolic diameter;
eptal thickness; EF, ejection fraction. Values are mean± S.D.
ymptomatic VT/VF was 214 for log BNP (95% CI
.2—37043, p = 0.04), 1.54 for DGE score (95% CI
.01—2.34, p = 0.04).
iscussion
nlarged area of DGE in CMR was associated with
ymptomatic VT/VF. This ﬁnding is compatible with
he previous reports that showed the relationship
etween the size of DGE in CMR and non-sustained
NS)/sustained VT documented by Holter monitor-
ng [7,8]. However, Dimitrow et al. have reported
hat the extent of DGE was not different between
atients with NSVT and those without NSVT even
hough DGE in CMR was more frequently observed
n patients with NSVT than those without NSVT
22]. However, 87% of their study population pre-
ented with dyspnea or exercise-induced angina
ectoris, while our patients were free from chest
ymptoms. Usefulness of DGE in CMR for predict-
ng life-threatening arrhythmia may be limited in
CM patients with symptoms of heart failure and
ngina. Further studies are necessary. Gadolinium-
TPA has been shown to distribute to extracellular
pace and cannot cross the intact sarcolemmal
embrane [23]. Tissue volume is predominantly
ntracellular in the normal myocardium (75—80%)
24]; thus, the distribution volume of gadolinium
s low in the normal heart. Extracellular space
s expanded in the presence of collagenous scar
150 K. Oka et al.
Figure 2 Representative ﬁndings of a patient with HCM without symptomatic VT/VF. A 70-year-old male patient was
referred to our hospital because of cardiac murmur and ECG abnormality. He was diagnosed as hypertrophic obstructive
cardiomyopathy with echocardiography. Plasma BNP concentration was 110 pg/ml and DGE score was 2. Long-axis view
at (A) end-systolic period and (B) end-diastolic period in cine-mode. Obstruction of left ventricular outﬂow tract was
mid,
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tobserved in systolic phase. DGE images at (C) base, (D)
Arrows indicate DGE positive segments that were found i
to increase the gadolinium concentration in the
tissue. Thus, it has been postulated that DGE in
CMR analysis is predominantly located in the area
where viable myocytes are absent and replaced
by ﬁbrosis in patients with HCM. Distribution of
DGE corresponded well to that of myocardial scar-
ring in necropsy in patients with HCM [5,6]. A case
report has shown that the area of DGE in CMR
represents regions of increased myocardial colla-
gen but not disarray [25]. Myocardial scarring is
thought to be caused by myocardial ischemia and
used as a substrate of ventricular tachyarrhyth-
mia [25]. Myocardial ischemia is common and
multifactorial in HCM [1]. Major causes include
impaired vasodilator reserve (perhaps related to
the thickened and narrowed small intramural coro-
nary arteries found in HCM) [4,26,27]; increased
oxygen demand, especially in patients with severe
myocardial hypertrophy and outﬂow gradients; and
B
w
c
L
tand (E) apical levels in the short-axis view are shown.
mid level of the short-axis view (segments 7 and 8).
levated ﬁlling pressures with resultant subendo-
ardial ischemia [1,28—30]. Impaired coronary ﬂow
eserve can predict poor prognosis of HCM patients
4,28]. In our study population, both DGE and
VMI were increased in patients with symptomatic
T/VF, and DGE was highly correlated with LVMI.
yocardial ischemia induced by severe myocardial
ypertrophy may cause VT/VF by forming myocar-
ial scarring, an arrythmogenic subject. DGE in CMR
hould be a useful marker for predicting high-risk
atients of sudden cardiac death in HCM.
We have also found, for the ﬁrst time, that
lasma BNP levels are higher in the VT/VF(+) group
han in the VT/VF(−) group. Plasma BNP/NT pro-
NP concentration has been shown to correlate
ith magnitude of heart failure symptoms and exer-
ise capacity [11—13], LV wall thickness [11—15],
V outﬂow tract obstruction [14,16], diastolic func-
ion [31,32], or silent myocardial ischemia [16] in
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Figure 3 Representative ﬁndings of a patient with HCM with symptomatic VT/VF. A 35-year-old male patient was
referred to our hospital because of sustained ventricular tachycardia. He was diagnosed with hypertrophic non-
obstructive cardiomyopathy with echocardiography. Plasma BNP concentration was 711 pg/ml, and DGE score was
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L0. DGE images at (A) base, (B) mid, (C) apical levels in t
rrows indicate DGE positive segments that were found a
2), and apical levels (segments 13, and 15).
atients with HCM. There were no patients with
ymptoms of heart failure in our study population,
nd the incidence of LV outﬂow tract obstruc-
ion at rest was similar in the VT/VF(+) group
nd VT/VF(−) group. Thus, increased LVMI appears
o be one of the causes of elevated plasma BNP
oncentration in our study population. However,
he correlation between plasma BNP levels and
VMI was weak and did not reach statistical signif-
cance (p = 0.07). Thus, it remains unknown what
s the major cause of different plasma BNP levels
etween VT/VF(+) group and VT/VF(−) group. So,
hat could be the cause of elevated plasma BNP
evels in patients with VT/VF? We again speculate
hat myocardial ischemia could be the one. Hypoxia
s a direct and sufﬁcient stimulus for BNP induction
n cardiomyocytes [33]. Plasma BNP levels are asso-
iated with silent myocardial ischemia detected by
xercise scintigraphy [16]. Plasma BNP level may be
T
t
o
V
tort-axis view, and (D) apex in long-axis view are shown.
se (segments 1, 3, 5, and 6), mid (segments 7, 9, 10 and
ncreased by myocardial ischemia, which is exac-
rbated not only by LV hypertrophy but also by
efective microcirculation in HCM patients. In our
tudy population, the correlation between plasma
NP levels and DGE score was weak and did not
each statistical signiﬁcance (p = 0.06). Plasma BNP
evel may be a marker of on-going ischemia, while
GE score may reﬂect both the intensity and dura-
ion of ischemia. Myocardial ischemia might cause
T/VF not only by scar formation in myocardium,
ut also by direct effect on cardiomyocytes in HCM.
imitations of the studyhree limitations of the study are noted. First,
he present study consisted of a small number
f patients because we focused on symptomatic
T/VF, but not on NSVT detected by Holter moni-
oring. We did not perform receiver operating curve
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Figure 4 Parameters in cardiac magnetic resonance imaging of the VT/VF(+) group (black bars) and the VT/VF(−)
group (white bars). (A) End-diastolic volume (EDV), (B) end-systolic volume (ESV), (C) left ventricular ejection frac-
ST),
S.D.
Rtion (LVEF), (D) interventricular septal wall thickness (IV
gadolinium enhancement (DGE) score. Values are mean±
analysis andmultivariate logistic regression analysis
with other known risk factors of sudden death such
as age and LV outﬂow obstruction because of a small
number of patients. Second, Holter monitoring was
not performed in many patients without symp-
tomatic VT/VF. However, NSVT in Holter monitoring
has high negative predictive accuracy (approx.
90%), but low positive predictive accuracy (22% or
lower) [1]. There may be some high-risk patients
for sudden cardiac death in the VT/VF(−) group,
but the number of high-risk patients may not be
large. Finally, we did not evaluate myocardial
ischemia in our study population. We speculated
that myocardial ischemia may link the enlarged
area of DGE in CMR, elevated plasma BNP lev-
els, and symptomatic VT/VF. Further studies are
necessary.
ConclusionsHigh plasma BNP levels and the enlarged area of
DGE were associated with symptomatic ventricu-
lar tachyarrhythmia. These factors may be useful
markers for detecting high-risk patients of sudden
cardiac death in HCM.(E) left ventricular mass index (LVMI), and (F) delayed
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